Meeting Minutes
North Dakota Medicaid Drug Use Review (DUR) Board
Meeting Date: March 1, 2023
Time and Location: 1:00 pm in Bismarck, North Dakota

Board Members:
Present: Andrea Honeyman, Gabriela Balf, Amy Werremeyer, Laura Kroetsch, Tanya Schmidt, Kevin Martian, Kristen Peterson, Josh Askvig, Kathleen Traylor
Absent: Stephanie Antony, Jennifer Iverson
Quorum Present: Yes

Others Present:
Medicaid Pharmacy Department: Brendan Joyce, LeNeika Roehrich, Jeff Hostetter

Meeting was called to order: A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:09 pm CST with Presiding Officer T. Schmidt presiding, and DUR Board Coordinator, L. Morgan recording minutes.

Administrative Items: There were no DHHS announcements at this meeting.

Approval of Meeting Minutes: Motion was made by J. Askvig, and seconded to approve the minutes of the December 7, 2022, meeting as distributed. **Motion carried.**

Reports:
Budget Update provided by B. Joyce
B. Joyce reported on hyper-cost drugs (i.e., Stelara, Dupixent, Humira, Hepatitis C agents), 30 drugs making up 47% of the Medicaid drug budget, and 6 drug classes (i.e., immunomodulators, oncology, cystic fibrosis, HIV) which account for 93% of increase in spend. The increase in drug spend is not attributable to the increase in members, but rather, it is from the increased use of hyper-cost drugs.

Review Top 25 Drugs provided by B. Joyce
B. Joyce presented the quarterly review of the top 25 drugs based on total cost of claims, the top 25 drugs based on the total number of claims, and the top drug classes based on claims and cost for the 4th quarter of 2022. This report can be found in the handout.

PDL/PA Criteria Updates provided by L.Roehrich
L. Roehrich shared with the Board all changes made to the Preferred Drug List (PDL) since the last update. This report can be found in the handout.

Update to C. difficile Associated Diarrhea (CDAD) provided by L. Morgan
L. Morgan discussed the addition of a CDAD prevention section to the PDL which listed criteria for Rebyota. This report can be found in the handout.

Update to Vaginal Infections provided by L. Morgan
L. Morgan discussed the “Fungal Infections” category to the “Vaginal Infections” section of the PDL along with updated criteria. There are now two categories (Bacterial and Fungal) which separate treatment options for either infection. This report can be found in the handout.

First Reviews: L. Morgan presented an overview of hyperparathyroidism, influenza, neuromyelitis optica spectrum disorder, and urea cycle agents. The presented material can be found in the handout.

Hyperparathyroidism:
Motion: Moved by A. Werremeyer for the Department to develop criteria for hyperparathyroidism, motion was seconded.

Influenza:
Motion: Moved by J. Askvig for the Department to develop criteria for influenza, motion was seconded.

Neuromyelitis Optica Spectrum Disorder:
Motion: Moved by J. Askvig for the Department to develop criteria for neuromyelitis optica spectrum disorder, motion was seconded.

Urea Cycle Agents:
Motion: Moved by L. Kroetsch for the Department to develop criteria for urea cycle agents, motion was seconded.

Discussion of Respiratory Syncytial Virus (RSV): L. Roehrich presented data from the Midwest region and, more specifically, North Dakota for the 2022 – 2023 RSV season. The data set for North Dakota from start-to-finish matched the Midwest Region of the RSV season, which was presented in a bell-shaped curve. This presentation confirms that following the CDC RSV positivity data allows for better representation and coverage for members during the RSV season. The presented material can be found in the handout.

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations: L. Morgan reviewed the RDUR criteria that were selected for review of each month of the last quarter. October consisted of a special mailing to prescribers of the buprenorphine monoproduct. The presented material can be found in the handout.
Motion: Moved by K. Martian to approve the RDUR criteria, motion was seconded. **Motion carried.**

Remicade Biosimilar Update: L. Roehrich presented a fax sent to providers discussing the preferred Remicade biosimilars effective January 1st, 2023. Biosimilars Avsola and Renflexis will not require prior authorization (PA). All other agents, Remicade, Inflectra, and infliximab will require PA. The presented material can be found in the handout.

Adjournment:
Motion: Moved by L. Kroetsch to adjourn the meeting, motion was seconded. **Motion carried.**

Meeting was adjourned at 2:15 pm CST.

Date of Minutes Approval:

Minutes submitted by: Lauren Morgan, Kepro